Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine

Clin Neuropharmacol. 1996 Oct;19(5):439-43. doi: 10.1097/00002826-199619050-00007.


Acute single-dose response of drug-induced parkinsonism (DIP) to L-Dopa and apomorphine challenge was evaluated in a double-blind crossover study in 12 schizophrenic patients. There were two noteworthy negative findings. First, neither L-Dopa nor apomorphine produced significant improvements in DIP and second, no changes (neither improvement nor worsening) were found in patients' psychiatric status. Findings suggest that, for a stimulation dose reaching almost 90% of the responsive dose for idiopathic Parkinson's disease, no significant changes may reasonably be expected in the parkinsonism of schizophrenic patients treated with neuroleptic drugs.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Analysis of Variance
  • Antiparkinson Agents / therapeutic use*
  • Antipsychotic Agents / adverse effects
  • Apomorphine / therapeutic use*
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Humans
  • Levodopa / therapeutic use*
  • Motor Activity / drug effects*
  • Parkinson Disease, Secondary / drug therapy*
  • Parkinson Disease, Secondary / etiology*
  • Parkinson Disease, Secondary / physiopathology
  • Psychiatric Status Rating Scales
  • Schizophrenia / chemically induced*
  • Schizophrenia / drug therapy*
  • Schizophrenia / physiopathology


  • Antiparkinson Agents
  • Antipsychotic Agents
  • Levodopa
  • Apomorphine